• 1
    Mulligan RM. Pathogenesis of teratoid tumors of the ovary and testis. Pathol Annu. 1975; 10: 271298.
  • 2
    Billmire D, Grosfeld J. Teratomas in childhood: analysis of 142 cases. J Pediatr Surg. 1986; 21: 54855.
  • 3
    Chretien P, Milam J, Foote F. Embryonal adenocarcinomas (a type of malignant teratoma) of the sacrococcygeal region. Clinical and pathologic aspects of 21 cases. Cancer. 1970; 26: 522535.
  • 4
    Kurman R, Norris H. Endodermal sinus tumor of the ovary. A clinical and pathologic analysis of 71 cases. Cancer. 1976; 38: 24042419.
  • 5
    Einhorn LH, Donohue J. Cis-diaminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977; 87: 293298.
  • 6
    Peckham MJ, Horwich A, Blackmore C, Hendry WF. Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma. Cancer Treat Rep. 1985; 69: 483488.
  • 7
    Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol. 1991; 9: 11631172.
  • 8
    Loehrer PJ Sr., Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995; 13: 470476.
  • 9
    Einhorn LH. Testicular cancer: an oncological success story. Clin Cancer Res. 1997; 12: 26302632.
  • 10
    Pinkerton C, Pritchard J, Spitz L. High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy. J Clin Oncol. 1986; 4: 194199.
  • 11
    Exelby PR. Testicular cancer in children. Cancer. 1980; 45(7 Suppl ): 18031809.
  • 12
    Dalgleish AG, Woods RL, Levi JA. Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol. 1984; 12: 313317.
  • 13
    Comis RL. Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol. 1992; 19(2 Suppl 5 ): 6470.
  • 14
    Mann JR, Pearson D, Barrett A, Raafat F, Barnes JM, Wallendszus KR. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies. Cancer. 1989; 63: 16571667.
  • 15
    Chiuten D, Vogl S, Kaplan B, Camacho F. Is there cumulative or delayed toxicity from cis-platinum?? Cancer. 1983; 52: 211214.
  • 16
    Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol. 2000; 18: 3809-3818.
  • 17
    Baranzelli MC, Kramar A, Bouffet E, et al. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. J Clin Oncol. 1999; 17: 12121218.
  • 18
    Gobel U, Bamberg M, Engert J, et al. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study]. Klin Padiatr. 1991; 203: 236245.
  • 19
    Gobel U, Calaminus G, Schneider DT, Schmidt P, Haas RJ. Management of germ cell tumors in children: approaches to cure. Onkologie. 2002; 25: 1422.
  • 20
    Gobel U, Schneider DT, Calaminus G, et al. Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. J Clin Oncol. 2001; 19: 19431950.
  • 21
    Ghosn M, Droz JP, Theodore C, et al. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen. Cancer. 1988; 62: 2427.
  • 22
    Ozols RF, Deisseroth AB, Javadpour N, Barlock A, Messerschmidt GL, Young RC. Treatment of poor prognosis nonseminomatous testicular cancer with a “high-dose” of platinum combination chemotherapy regimen. Cancer. 1983; 51: 1803-1807.
  • 23
    Hartmann O, Pinkerton CR, Philip T, Zucker JM, Breatnach F. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol. 1988; 6: 4450.
  • 24
    Perin G, Dallorso S, Stura M, et al. High-dose cisplatin and etoposide in advanced malignancies of childhood. Pediatr Hematol Oncol. 1987; 4: 329336.
  • 25
    Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol. 2004; 22: 2691-2700.
  • 26
    Fulda S, Oster W, Berthold F. Effects of wr-2721 (amifostine) and its metabolite wr-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro. Anticancer Drugs. 1997; 8: 3441.
  • 27
    Borsi JD, Csaki C, Ferencz T, Oster W. Administration of ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin. Anticancer Drugs. 1996; 7: 121126.
  • 28
    Adamson PC, Balis FM, Belasco JE, et al. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 1995; 55: 40694072.
  • 29
    Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer. 1997; 80: 11341140.
  • 30
    Glover D, Glick JH, Weiler C, Fox K, Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol. 1987; 5: 574578.
  • 31
    Glover D, Glick JH, Weiler C, Hurowitz S, Kligerman MM. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol. 1986; 4: 584588.
  • 32
    Wadler S, Beitler JJ, Rubin JS, et al. Pilot trial of cisplatin, radiation, and wr2721 in carcinoma of the uterine cervix: a New York gynecologic oncology group study. J Clin Oncol. 1993; 11: 15111516.
  • 33
    Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996; 14: 21012112.
  • 34
    Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991; 19: 295300.
  • 35
    Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004; 40: 24452451.
  • 36
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 37
    Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Series A. 1972; 135: 185198.
  • 38
    Einhorn LH. Combination chemotherapy with cis-dichlorodiammineplatinum(II) in disseminated testicular cancer. Cancer Treat Rep. 1979; 63: 16591662.
  • 39
    Einhorn LH, Williams SD. Chemotherapy of disseminated testicular cancer. West J Med. 1979; 131: 13.
  • 40
    Katzenstein HM, Chang K, Krailo M, et al. A randomized study of platinum based chemotherapy with or without amifostine for the treatment of children with hepatoblastoma (HB): a report of the Intergroup Hepatoblastoma Study P9645 [abstract]. Am Soc Clin Oncol. 2004; 22: 8518.
  • 41
    Fisher MJ, Lange BJ, Needle MN, et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2004; 43: 780784.